ArticleeLife2018
Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- CD8+ T cell activation in endometrial cancer: prognostic implications and potential for personalized therapy.Frontiers in immunology · 2025Article
- Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids.Journal of translational medicine · 2024Article
- Predicting therapeutic responses in head and neck squamous cell carcinoma fromTranslational cancer research · 2023Article
- Overexpression of TWF1 promotes lung adenocarcinoma progression and is associated with poor prognosis in cancer patients through the MMP1 signaling pathway.Journal of thoracic disease · 2023Article
- FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.Cancer medicine · 2023Article
- Association ofFrontiers in genetics · 2022Article
- Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics.Frontiers in genetics · 2022Article
- ComprehensiveFrontiers in immunology · 2022Article
- Article
- Significance and Mechanisms Analyses ofBladder cancer (Amsterdam, Netherlands) · 2021Article
- Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma.Nature communications · 2019Article
- Article
- Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data.Scientific reports · 2019Article
- Significance of PTEN Mutation in Cellular Process, Prognosis, and Drug Selection in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2019Article
- Article
- On the low reproducibility of cancer studies.National science review · 2018Article
- Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.The Journal of clinical investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2016, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Vanden Heuvel et al., 2016), that described how we intended to replicate selected experiments from the paper 'Systematic identification of genomic markers of drug sensitivity in cancer cells' (Garnett et al., 2012). Here we report the results. We found Ewing's sarcoma cell lines, overall, were more sensitive to the PARP inhibitor olaparib than osteosarcoma cell lines; however, while the effect was in the same direction as the original study (Figure 4C; Garnett et al., 2012), it was not statistically significant. Further, mouse mesenchymal cells transformed with either the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.